Recent findings suggest that tardive dyskinesia may involve GABA-ergic influences in addition to dopaminergic receptor hypersensitivity and relative cholinergic hypofunction. Sodium valproate, which may increase brain GABA, moderately reduced tardive dyskinesia with doses of 900-3000 mg/day, as measured by a tremor-graph and rating scales. There was no correlation between dosage, blood levels, or clinical response. Although the symptoms were not completely controlled, valproate and other GABA-ergic agents may be useful compounds in studying and treating tardive dyskinesia.
|Original language||English (US)|
|Number of pages||3|
|Journal||Journal of Clinical Psychiatry|
|State||Published - Dec 1 1979|
ASJC Scopus subject areas
- Psychiatry and Mental health